DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» McDonald criteria
McDonald criteria
Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity
Fingolimod (Gilenya)
Oral MS Disease-Modifying Therapies C21142-A
Multiple Sclerosis Research: Diagnostics, Disease-Modifying
Multiple Sclerosis
Tecfidera (Dimethyl Fumarate) Policy Number: C3891-A
Updated Criteria for Diagnosing Multiple Sclerosis
Utilization Review Policy 139 Disease Overview
The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
(Pre-Allison & Millar) Ipsen Criteria: 1939-48, Boston, MA
Consensus Definitions for Pediatric MS and Other Demyelinating Disorders in Childhood
Characterizing Absolute Lymphocyte Count Profiles in Dimethyl Fumarate–Treated Patients with MS
Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multi
Page 1 of 4 Clinical Policy: Dimethyl Fumarate (Tecfidera)
Mavenclad (Cladribine) Effective 12/1/2019
Delayed-Release Dimethyl Fumarate As Add-On Therapy to Beta
Swedish Neuroscience Institute
Nerventra Laquinimod
Top View
Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Multiple Sclerosis: a Review and Treatment Option Updates
Acute Disseminated Encephalomyelitis in Children: Differential Diagnosis from Multiple Sclerosis on the Basis of Clinical Course
Cladribine in the Treatment of Multiple Sclerosis
Long-Term Effects of Cladribine Tablets on MRI Activity Outcomes in Patients
Comparative Immunopathogenesis of Acute Disseminated Encephalomyelitis, Neuromyelitis Optica, and Multiple Sclerosis Dean M
Acute Fulminant Demyelinating Disease a Descriptive Study of 60 Patients
Implementing the 2017 Mcdonald Criteria for the Diagnosis of Multiple
PM118 Alemtuzumab (Lemtrada)
Dimethyl Fumarate) Policy Number: C3891-A
MR Imaging Criteria Differentiating Asymptomatic PML from New MS Lesions During Natalizumab
Isolated Palatal Weakness Without Optic Neuritis As the Presenting
Study Protocol
Multiple Sclerosis
Multiple Sclerosis Agents Prior Authorization with Quantity Limit - Through Preferred Agent Program Summary
The Characteristics of Acute Disseminated Encephalomyelitis
Tysabri PRIOR AUTHORIZATION CRITERIA
Multiple Sclerosis IV
Multiple Sclerosis EOCCO POLICY
Proposed Modifications to Mcdonald Diagnostic Criteria for Asians with Multiple Sclerosis
Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies
Tysabri® (Natalizumab) Injection
Oral Ponesimod in Relapsing–Remitting Multiple Sclerosis: A
Tysabri, INN-Natalizumab
Clinical Study Protocol with Global Amendment 02
The Efficacy of Cladribine Tablets in CIS Patients Retrospectively
Tysabri® (Natalizumab)
Evolution of Diagnostic Criteria for Multiple Sclerosis: Implications for Clinical Trials
FREEDOMS Fact Sheet
PM126 Natalizumab (Tysabri)
Mcdonald Criteria
GILENYA (Fingolimod) MAVENCLAD (Cladrabine) MAYZENT (Siponimod) PONVORY (Ponesimod) TECFIDERA (Dimethyl Fumarate) VUMERITY (Diroximel Fumarate) ZEPOSIA (Ozanimod)
New MS Criteria Aim to Simplify Diagnosis
Multiple Sclerosis
Mavenclad (Cladribine) Oral Dosage Forms Annual Review Date
Cerebrospinal Fluid Analysis in the Context of CNS Demyelinating
Lemtrada® (Alemtuzumab)
Mavenclad (Cladribine)